Editorial on “What FDG-PET response-assessment method best predicts survival after curative-intent chemoradiation in non-small cell lung cancer (NSCLC): EORTC, PERCIST, Peter Mac or Deauville criteria?”

The treatment of non-small cell lung cancer (NSCLC) is fortunately an expanding field. Many new treatment regimens are emerging, with second, third, and fourth line therapies. This inadvertently results in a need for a reliable, early evaluation of the treatment response, during or at the end of treatment, enabling a more personalized treatment planning. Treatment response with FDG-PET/CT is an excellent candidate since the metabolic response evaluated with this modality precedes the anatomical response traditionally measured with CT scans and has been shown to be a promising tool in NSCLC (1-4). The variation in how to measure and report a response with FDG-PET/CT is large, rendering the comparison of studies on this subject very difficult